Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity

Takuji Ishimoto, Yoshifumi Takei, Yukio Yuzawa, Koji Hanai, Shunji Nagahara, Yuzo Tarumi, Seiichi Matsuo, Kenji Kadomatsu

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Contact hypersensitivity (CHS) is a common skin disease, presenting clinically as allergic contact dermatitis. At inflammatory sites in a typical CHS model in the mouse ear, elevated expression of monocyte chemoattractant protein-1 (MCP-1) has been reported. MCP-1 is a potent chemotactic factor for many types of leukocytes including monocytes/ macrophages and T cells. In this study, we aimed at developing a therapy for CHS involving RNA interference targeting MCP-1. A short interfering RNA (siRNA) to mouse MCP-1 successfully inhibited the secretion of MCP-1 by a fibroblastic cell line, L929, and RAW 264.7 cells derived from macrophages, and strikingly suppressed ear swelling in a CHS model. The siRNA systemically administered inhibited the infiltration of both monocytes/macrophages and T cells in the CHS model. Atelocollagen was used in this therapy as a delivery reagent for siRNA into the animal body. Atelocollagen facilitated the incorporation of the siRNA into macrophages/monocytes and fibroblasts, which vigorously secrete MCP-1 protein at inflammatory sites in CHS. This therapy had no adverse effects such as induction of interferon, or liver or renal damage. Our data indicate that the systemic delivery of siRNA targeting MCP-1 is a potent therapeutic strategy for CHS treatment.

Original languageEnglish
Pages (from-to)387-395
Number of pages9
JournalMolecular Therapy
Volume16
Issue number2
DOIs
Publication statusPublished - 01-01-2008
Externally publishedYes

Fingerprint

Haptens
Chemokine CCL2
Contact Dermatitis
Small Interfering RNA
Down-Regulation
Macrophages
Monocytes
Ear
T-Lymphocytes
Allergic Contact Dermatitis
Chemotactic Factors
Therapeutics
RNA Interference
Skin Diseases
Interferons
Leukocytes
Fibroblasts
Kidney
Cell Line
Liver

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Ishimoto, Takuji ; Takei, Yoshifumi ; Yuzawa, Yukio ; Hanai, Koji ; Nagahara, Shunji ; Tarumi, Yuzo ; Matsuo, Seiichi ; Kadomatsu, Kenji. / Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. In: Molecular Therapy. 2008 ; Vol. 16, No. 2. pp. 387-395.
@article{1ec5559958ff46e8bc54551a18520b5b,
title = "Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity",
abstract = "Contact hypersensitivity (CHS) is a common skin disease, presenting clinically as allergic contact dermatitis. At inflammatory sites in a typical CHS model in the mouse ear, elevated expression of monocyte chemoattractant protein-1 (MCP-1) has been reported. MCP-1 is a potent chemotactic factor for many types of leukocytes including monocytes/ macrophages and T cells. In this study, we aimed at developing a therapy for CHS involving RNA interference targeting MCP-1. A short interfering RNA (siRNA) to mouse MCP-1 successfully inhibited the secretion of MCP-1 by a fibroblastic cell line, L929, and RAW 264.7 cells derived from macrophages, and strikingly suppressed ear swelling in a CHS model. The siRNA systemically administered inhibited the infiltration of both monocytes/macrophages and T cells in the CHS model. Atelocollagen was used in this therapy as a delivery reagent for siRNA into the animal body. Atelocollagen facilitated the incorporation of the siRNA into macrophages/monocytes and fibroblasts, which vigorously secrete MCP-1 protein at inflammatory sites in CHS. This therapy had no adverse effects such as induction of interferon, or liver or renal damage. Our data indicate that the systemic delivery of siRNA targeting MCP-1 is a potent therapeutic strategy for CHS treatment.",
author = "Takuji Ishimoto and Yoshifumi Takei and Yukio Yuzawa and Koji Hanai and Shunji Nagahara and Yuzo Tarumi and Seiichi Matsuo and Kenji Kadomatsu",
year = "2008",
month = "1",
day = "1",
doi = "10.1038/sj.mt.6300360",
language = "English",
volume = "16",
pages = "387--395",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. / Ishimoto, Takuji; Takei, Yoshifumi; Yuzawa, Yukio; Hanai, Koji; Nagahara, Shunji; Tarumi, Yuzo; Matsuo, Seiichi; Kadomatsu, Kenji.

In: Molecular Therapy, Vol. 16, No. 2, 01.01.2008, p. 387-395.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity

AU - Ishimoto, Takuji

AU - Takei, Yoshifumi

AU - Yuzawa, Yukio

AU - Hanai, Koji

AU - Nagahara, Shunji

AU - Tarumi, Yuzo

AU - Matsuo, Seiichi

AU - Kadomatsu, Kenji

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Contact hypersensitivity (CHS) is a common skin disease, presenting clinically as allergic contact dermatitis. At inflammatory sites in a typical CHS model in the mouse ear, elevated expression of monocyte chemoattractant protein-1 (MCP-1) has been reported. MCP-1 is a potent chemotactic factor for many types of leukocytes including monocytes/ macrophages and T cells. In this study, we aimed at developing a therapy for CHS involving RNA interference targeting MCP-1. A short interfering RNA (siRNA) to mouse MCP-1 successfully inhibited the secretion of MCP-1 by a fibroblastic cell line, L929, and RAW 264.7 cells derived from macrophages, and strikingly suppressed ear swelling in a CHS model. The siRNA systemically administered inhibited the infiltration of both monocytes/macrophages and T cells in the CHS model. Atelocollagen was used in this therapy as a delivery reagent for siRNA into the animal body. Atelocollagen facilitated the incorporation of the siRNA into macrophages/monocytes and fibroblasts, which vigorously secrete MCP-1 protein at inflammatory sites in CHS. This therapy had no adverse effects such as induction of interferon, or liver or renal damage. Our data indicate that the systemic delivery of siRNA targeting MCP-1 is a potent therapeutic strategy for CHS treatment.

AB - Contact hypersensitivity (CHS) is a common skin disease, presenting clinically as allergic contact dermatitis. At inflammatory sites in a typical CHS model in the mouse ear, elevated expression of monocyte chemoattractant protein-1 (MCP-1) has been reported. MCP-1 is a potent chemotactic factor for many types of leukocytes including monocytes/ macrophages and T cells. In this study, we aimed at developing a therapy for CHS involving RNA interference targeting MCP-1. A short interfering RNA (siRNA) to mouse MCP-1 successfully inhibited the secretion of MCP-1 by a fibroblastic cell line, L929, and RAW 264.7 cells derived from macrophages, and strikingly suppressed ear swelling in a CHS model. The siRNA systemically administered inhibited the infiltration of both monocytes/macrophages and T cells in the CHS model. Atelocollagen was used in this therapy as a delivery reagent for siRNA into the animal body. Atelocollagen facilitated the incorporation of the siRNA into macrophages/monocytes and fibroblasts, which vigorously secrete MCP-1 protein at inflammatory sites in CHS. This therapy had no adverse effects such as induction of interferon, or liver or renal damage. Our data indicate that the systemic delivery of siRNA targeting MCP-1 is a potent therapeutic strategy for CHS treatment.

UR - http://www.scopus.com/inward/record.url?scp=38649095979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649095979&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300360

DO - 10.1038/sj.mt.6300360

M3 - Article

C2 - 18059372

AN - SCOPUS:38649095979

VL - 16

SP - 387

EP - 395

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -